Tumor: is an abnormal mass of tissue that may be solid or fluid-filled. A tumor is not the same as cancer. Although, some tumors can develop into cancers. A tumor is a kind of lump or swelling and does not necessarily pose a health threat.
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro...
FTIR spectroscopic imaging is an emerging tool for label-free, non-destructive characterization of tissues. The pathological annotation of tissue can be performed in an automated and objectiv...
The ability to measure changes to DNA, RNA, and protein across cell types is crucial to understanding the immune response to the environment or therapeutic treatment. NanoString Technologies...
Hepatocellular Carcinoma (HCC) and Endometrioid Endometrial Carcinoma (EEC) are two lethal diseases of public health importance worldwide. Understanding the mechanisms of tumor progression in...
The talk will first report on a new patented method of counting CTCs based on the metabolism of tumor cells, that favors acidification of their near environment. In order to maintain the acid...
Tumor heterogeneity has been known for a while but quantifying heterogeneity is still a challenge. NGS is the method of choice in the analysis of tumor heterogeneity, however, there are...
DATE: September 28, 2016TIME: 9:00am Pacific time, 12:00pm Eastern timeNK cells play critical roles in immune defense and reproduction but remain the most poorly under...
The field of infectious disease diagnostics is ever changing with both newly identified infections such as SARS, Ebola, and Zika virus as well as yearly epidemics and potential for pandemic w...
In our previous preclinical studies, when neural stem progenitor cells (NS/PCs)-derived from hiPSCs were transplanted into mouse or non-human primate spinal cord injury (SCI) models, long-ter...
DATE: July 20thTIME: 8AM PT, 11AM ET, 5PM CESTTherapies like ipilimumab and nivolumab have shown the potential for approaches that direct the patient’s own immune system aga...
Hepatocellular Carcinoma (HCC), the third leading cause of global cancer mortality, continues to be a substantial burden to health systems, society and individuals at risk. Although prognosis...
DATE: June 30, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the...
DATE: June 15, 2016TIME: 08:00AM PDT, 11:00AM EDT, 3:00PM GMT Positron Emission Tomography (PET) is a 3-dimensional, quantitative imaging technology that has robust clinical trans...
Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses a...
In order to realize the benefits of personalized cancer therapy, increasing demands are placed upon clinical laboratories to provide timely, comprehensive, clinically actionable, and analytic...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
Human breast tumors have been shown to exhibit extensive inter- and intra-tumor heterogeneity. While recent advances in genomic technologies have allowed us to deconvolute this heterogeneity,...
Imaging-based techniques have traditionally been restricted to the diagnosis and staging of cancer. But technological advances are moving imaging modalities into the heart of patient care. Im...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and inter...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Detection of mutational alterations is important for guiding treatment decisions of lung non-small cell carcinomas and thyroid nodules with atypical cytologic findings. Inoperable lung tumors...
Success of the personalized medicine strategy depends on our ability to access the genetic variance landscape continuously before, during and after treatment. Liquid biopsies provide us...
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro...
FTIR spectroscopic imaging is an emerging tool for label-free, non-destructive characterization of tissues. The pathological annotation of tissue can be performed in an automated and objectiv...
The ability to measure changes to DNA, RNA, and protein across cell types is crucial to understanding the immune response to the environment or therapeutic treatment. NanoString Technologies...
Hepatocellular Carcinoma (HCC) and Endometrioid Endometrial Carcinoma (EEC) are two lethal diseases of public health importance worldwide. Understanding the mechanisms of tumor progression in...
The talk will first report on a new patented method of counting CTCs based on the metabolism of tumor cells, that favors acidification of their near environment. In order to maintain the acid...
Tumor heterogeneity has been known for a while but quantifying heterogeneity is still a challenge. NGS is the method of choice in the analysis of tumor heterogeneity, however, there are...
DATE: September 28, 2016TIME: 9:00am Pacific time, 12:00pm Eastern timeNK cells play critical roles in immune defense and reproduction but remain the most poorly under...
The field of infectious disease diagnostics is ever changing with both newly identified infections such as SARS, Ebola, and Zika virus as well as yearly epidemics and potential for pandemic w...
In our previous preclinical studies, when neural stem progenitor cells (NS/PCs)-derived from hiPSCs were transplanted into mouse or non-human primate spinal cord injury (SCI) models, long-ter...
DATE: July 20thTIME: 8AM PT, 11AM ET, 5PM CESTTherapies like ipilimumab and nivolumab have shown the potential for approaches that direct the patient’s own immune system aga...
Hepatocellular Carcinoma (HCC), the third leading cause of global cancer mortality, continues to be a substantial burden to health systems, society and individuals at risk. Although prognosis...
DATE: June 30, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the...
DATE: June 15, 2016TIME: 08:00AM PDT, 11:00AM EDT, 3:00PM GMT Positron Emission Tomography (PET) is a 3-dimensional, quantitative imaging technology that has robust clinical trans...
Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses a...
In order to realize the benefits of personalized cancer therapy, increasing demands are placed upon clinical laboratories to provide timely, comprehensive, clinically actionable, and analytic...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
Human breast tumors have been shown to exhibit extensive inter- and intra-tumor heterogeneity. While recent advances in genomic technologies have allowed us to deconvolute this heterogeneity,...
Imaging-based techniques have traditionally been restricted to the diagnosis and staging of cancer. But technological advances are moving imaging modalities into the heart of patient care. Im...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and inter...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Detection of mutational alterations is important for guiding treatment decisions of lung non-small cell carcinomas and thyroid nodules with atypical cytologic findings. Inoperable lung tumors...
Success of the personalized medicine strategy depends on our ability to access the genetic variance landscape continuously before, during and after treatment. Liquid biopsies provide us...
Follow
